New Eli Lilly Data Puts Verzenio In Breast Cancer Spotlight

Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate significant progress in survival outcomes for high-risk early breast cancer patients.

Eli Lilly and Co. (NYSE:LLY) on Wednesday released topline results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial.

Treatment with two years of Verzenio plus endocrine therapy (ET) demonstrated a statistically significant and clinically meaningful improvement in OS compared to ET alone in patients with hormone receptor positive ...